Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

FGF-23 and Endothelial Dysfunction in Diabetic Proteinuric Patients

This study has been completed.
Information provided by (Responsible Party):
Mahmut Ilker Yilmaz, Gulhane School of Medicine Identifier:
First received: October 4, 2012
Last updated: October 6, 2012
Last verified: October 2012
There is no data about the effects of Renin angiotensin system blockage (RAS) on FGF23 and ADMA levels in diabetic patients with proteinuria. The aim of this study was to find out whether the beneficial effects of RAS blockage in diabetic proteinuria has any relation with the alteration of ADMA and FGF-23 levels. We searched for the effects of ACE inhibitor ramipril on the clinical and laboratory parameters of diabetic patients with proteinuria.

Condition Intervention Phase
Diabetic Nephropathy
Chronic Kidney Disease
Drug: Ramipril
Phase 4

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Gulhane School of Medicine:

Primary Outcome Measures:
  • Flow Mediated Dilatation

Secondary Outcome Measures:
  • FGF-23

Enrollment: 78
Study Start Date: January 2008
Study Completion Date: April 2009
Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Ramipril Drug: Ramipril
ramipril 10 mg/day during 3 months

  Show Detailed Description


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • CKD stage 1 patients
  • Older than 18 years of age
  • Type 2 Diabetic patients
  • Proteinuria

Exclusion Criteria:

  • History of coronary artery disease
  • Smokers
  • Taking statins or renin-angiotensin blockers
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01703234

Gulhane School of Medicine
Ankara, Turkey
Sponsors and Collaborators
Gulhane School of Medicine
  More Information

Responsible Party: Mahmut Ilker Yilmaz, Assoc.Prof., Gulhane School of Medicine Identifier: NCT01703234     History of Changes
Other Study ID Numbers: GATARAMFGF232012 
Study First Received: October 4, 2012
Last Updated: October 6, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Gulhane School of Medicine:
FGF-23 , ramipril, endothelial dysfunction

Additional relevant MeSH terms:
Kidney Diseases
Renal Insufficiency, Chronic
Diabetic Nephropathies
Urologic Diseases
Renal Insufficiency
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Urination Disorders
Urological Manifestations
Signs and Symptoms
Angiotensin-Converting Enzyme Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antihypertensive Agents processed this record on October 27, 2016